Development of a digital and self-instructing home test for different types of asthma.
| Reference number | |
| Coordinator | Medituner AB |
| Funding from Vinnova | SEK 2 551 107 |
| Project duration | June 2019 - December 2022 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
Important results from the project
The aim of the project was to develop a simple, self-instructing home test for different types of asthma. The goal was to develop a digital evaluation tool and self-test, where patients can test on their own for several different types of common asthma triggers (e.g. exertional asthma and allergic asthma). The digital evaluation tool is now available to patients, and notifies when sufficient measurements has been collected in. Data is shared with the healthcare in a structured way to effectively guide doctors for a fast and safe objectively verified diagnosis.
Expected long term effects
Asthma is underdiagnosed and it is anticipated that this project will lead to earlier diagnosis and better management of asthma which will translate into better quality of life for people affected by asthma. Good treatment of asthma requires early diagnosis and an accurate assessment of its severity. We anticipate this project will reduce the number of clinic visits whilst improving accessibility. The assessment can be started immediately while the patient is experiencing symptoms independent of when an appointment is available (by which time the symptoms may well have resolved).
Approach and implementation
** Denna text är maskinöversatt ** The planned structure contained four categories: Requirements and product design: Market analysis and ensure correct CE marking strategy. Technical development: Validate requirements, plan development, carry out development and test end results. Validation: Detailed study structure, seek ethics approval and carry out the study. Commercialization: Production of business plan and market research among consumers. Implementation of the scheme has followed the plan, except for delays in the clinical study due to covid-19.